CD19t
Recurrent Glioma
City of Hope Medical CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
95 Active assets in the Recurrent Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olutasidenib Rigel Pharmaceuticals | Phase 4 | BBB |
Irinotecan Kailin Yang, MD, PhD | Phase 3 | B |
Valproic Acid Medical University of South Carolina | Phase 2 | B |
DIANHYDROGALACTITOL Kintara Therapeutics, Inc. | Phase 2 | B |
Cyclophosphamide Essen Biotech | Phase 2 | B |
View all 50 →
Same molecule, other indications
CD19t is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →